MENU
ABBV
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

ABBV stock forecast, quote, news & analysis

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more

ABBV
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for ABBV with price predictions
Oct 02, 2026

ABBV in upward trend: price rose above 50-day moving average on September 10, 2026

ABBV moved above its 50-day moving average on September 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +0.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 218 of 357 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 38 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 20 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 43%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.199). ABBV has a moderately high P/E Ratio (75.220) as compared to the industry average of (34.793). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.026) settles around the average of (0.025) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

ABBV is expected to pay dividends on November 16, 2026

ABBVIE ABBV Stock Dividends
A quarterly dividend of $1.73 per share will be paid with a record date of November 16, 2026, and an ex-dividend date of October 15, 2026. The last dividend of $1.73 was paid on August 14. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 200.13B. The market cap for tickers in the group ranges from 4.8K to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was 8%. NSRX experienced the highest price growth at 13%, while MIRA experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 30%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was 4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 27
P/E Growth Rating: 53
Price Growth Rating: 55
SMR Rating: 59
Profit Risk Rating: 64
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
ABBV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com